Dose Recommendations for Common Drugs in Patients with Liver Cirrhosis: A Systematic Literature Review
Tóm tắt
The presence of liver cirrhosis affects the selection and dosing of drugs metabolised by the liver as doses have to be adjusted to the remaining liver function. This is a major challenge in clinical practice as specific guidelines are lacking. The aim of this study was to identify drugs for which recommendations on selection and dose adjustments for patients with cirrhosis exist by assessing the literature according to certain quality standards, paying particular attention to the suitability of these recommendations for clinical practice. A systematic literature review included peer-reviewed publications that were published by October 2020 in PubMed in the English language and aimed to generate recommendations on dose adjustment in patients with liver cirrhosis. Subsequently, the identified publications were checked for reporting quality against the relevant reporting guidelines and the Oxford Centre for Evidence-Based Medicine Levels of Evidence. Finally, all specific dose recommendations were extracted, compared with the specifications of the Summaries of Product Characteristics and mapped according to the Anatomical Therapeutic Chemical/Defined Daily Dose Index. Eighteen publications covering a total of 1145 dose recommendations for 481 active substances were identified. There were 706 recommendations for 316 substances sufficiently specific for application in clinical practice. For 22 active substances, the specific recommendations were consistent across multiple publications, of which only six were also consistent with the respective Summaries of Product Characteristics. As the majority of dose recommendations were not sufficiently specific or even contradictory, there is an urgent need for the definition of standard parameters for a uniform assessment of drugs in liver cirrhosis. In addition, dose recommendations should be aligned by suitable methods.
Tài liệu tham khảo
Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379–407. https://doi.org/10.2165/00002018-200730050-00003.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838–51. https://doi.org/10.1016/S0140-6736(08)60383-9.
Gonzalez M, Goracci L, Cruciani G, Poggesi I. Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease. Expert Opin Drug Metab Toxicol. 2014;10(10):1397–408. https://doi.org/10.1517/17425255.2014.952628.
Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61. https://doi.org/10.1007/s00228-008-0553-z.
Franz CC, Hildbrand C, Born C, Egger S, Rätz Bravo AE, Krähenbühl S. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Eur J Clin Pharmacol. 2013;69(8):1565–73. https://doi.org/10.1007/s00228-013-1502-z.
Cheema E, Al-Aryan A, Al-Hamid A. Medicine use and medicine-related problems in patients with liver cirrhosis: a systematic review of quantitative and qualitative studies. Eur J Clin Pharmacol. 2019;75(8):1047–58. https://doi.org/10.1007/s00228-019-02688-z.
Weisbach L, Schuster AK, Hartmann M, Fromm MF, Maas R, Farker K. Inconsistencies and ambiguities in liver-disease-related contraindications: a systematic analysis of SmPCs/PI of major drug markets. J Clin Med. 2022;11(7):1933. https://doi.org/10.3390/jcm11071933.
Weersink RA, Timmermans L, Monster-Simons MH, Mol PGM, Metselaar HJ, Borgsteede SD, et al. Evaluation of information in Summaries of Product Characteristics (SmPCs) on the use of a medicine in patients with hepatic impairment. Front Pharmacol. 2019;10:1031. https://doi.org/10.3389/fphar.2019.01031.
Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, et al. Evidence-based recommendations to improve the safe use of drugs in patients with liver cirrhosis. Drug Saf. 2018;41(6):603–13. https://doi.org/10.1007/s40264-017-0635-x.
Halilovic J, Heintz BH. Antibiotic dosing in cirrhosis. Am J Health Syst Pharm. 2014;71(19):1621–34. https://doi.org/10.2146/ajhp140031.
Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf. 1997;17(1):47–73. https://doi.org/10.2165/00002018-199717010-00004.
Wohlin C. Guidelines for snowballing in systematic literature studies and a replication in software engineering. In: Proceedings of the 18th International Conference on Evaluation and Assessment in Software Engineering—EASE ‘14. New York: ACM Press; 2014. pp. 1–10.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3(3):e123–30. https://doi.org/10.1371/journal.pmed.1000097.
Brouwers MC, Kerkvliet K, Spithoff K. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;352:1152. https://doi.org/10.1136/bmj.i1152.
Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31(8):684–706. https://doi.org/10.1177/0269216317690685.
OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. 2023. http://www.cebm.net/index.aspx?o=5653. Accessed 13 Jan 2023.
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2022. 2022. https://www.whocc.no/atc_ddd_index/. Accessed 13 Jan 2023.
Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer “atypical” antipsychotics: part 3. Effects of renal and hepatic impairment. J Psychiatr Pract. 2012;18(6):430–7. https://doi.org/10.1097/01.pra.0000422741.95118.9f.
Gangopadhyay KK, Singh P. Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment. Indian J Endocrinol Metab. 2017;21(2):341–54. https://doi.org/10.4103/ijem.IJEM_512_16.
Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005;40(1):174–81. https://doi.org/10.1086/426021.
Periáñez-Párraga L, Martínez-López I, Ventayol-Bosch P, Puigventós-Latorre F, Delgado-Sánchez O. Drug dosage recommendations in patients with chronic liver disease. Rev Esp Enferm Dig. 2012;104(4):165–84. https://doi.org/10.4321/s1130-01082012000400002.
Klotz U. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet. 2007;46(12):985–96. https://doi.org/10.2165/00003088-200746120-00002.
Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis: a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132–56. https://doi.org/10.1111/apt.12324.
Harris DG. Management of pain in advanced disease. Br Med Bull. 2014;110(1):117–28. https://doi.org/10.1093/bmb/ldu010.
Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, et al. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84(8):1806–20. https://doi.org/10.1111/bcp.13615.
Westphal JF, Brogard JM. Clinical pharmacokinetics of newer antibacterial agents in liver disease. Clin Pharmacokinet. 1993;24(1):46–58. https://doi.org/10.2165/00003088-199324010-00004.
Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet. 1999;37(5):399–431. https://doi.org/10.2165/00003088-199937050-00004.
Schlatter C, Egger SS, Tchambaz L, Krähenbühl S. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. Drug Saf. 2009;32(7):561–78. https://doi.org/10.2165/00002018-200932070-00003.
Haanpää ML, Gourlay GK, Kent JL, Miaskowski C, Raja SN, Schmader KE, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc. 2010;85(3 Suppl.):S15-25. https://doi.org/10.4065/mcp.2009.0645.
Anderson GD, Hakimian S. Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. Clin Pharmacokinet. 2014;53(1):29–49. https://doi.org/10.1007/s40262-013-0107-0.
Dwyer JP, Jayasekera C, Nicoll A. Analgesia for the cirrhotic patient: a literature review and recommendations. J Gastroenterol Hepatol. 2014;29(7):1356–60. https://doi.org/10.1111/jgh.12560.
Imani F, Motavaf M, Safari S, Alavian SM. The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations. Hepat Mon. 2014;14(10):e23539. https://doi.org/10.5812/hepatmon.23539.
Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. Clin Pharmacokinet. 2014;53(12):1069–81. https://doi.org/10.1007/s40262-014-0187-5.
Vasakova M. Challenges of antituberculosis treatment in patients with difficult clinical conditions. Clin Respir J. 2015;9(2):143–52. https://doi.org/10.1111/crj.12119.
Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int. 2004;73(4):289–95. https://doi.org/10.1159/000081585.
Weersink RA, Burger DM, Hayward KL, Taxis K, Drenth JPH, Borgsteede SD. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2020;16(1):45–57. https://doi.org/10.1080/17425255.2020.1702022.
Dalkey N, Helmer O. An experimental application of the DELPHI method to the use of experts. Manage Sci. 1963;9(3):458–67.